Related Experiment Video
Updated: May 12, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Triptan nonresponders: do they exist and who are they?
Michele Viana1, Armando A Genazzani, Salvatore Terrazzino
1Headache Science Center, C. Mondino National Institute of Neurology Foundation, IRCCS, Pavia, Italy. michele.viana@mondino.it
Cephalalgia : an International Journal of Headache
|April 9, 2013
Summary
Identifying triptan nonresponders is crucial for effective migraine treatment. Current data are insufficient to define a triptan nonresponder population, necessitating further research into treatment-resistant migraines.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Triptans are a primary treatment for migraines, but efficacy varies.
- Approximately 30-40% of patients show inadequate response to triptan therapy.
- Failure of one triptan does not predict failure of another, complicating patient classification.
Purpose of the Study:
- To highlight the importance of identifying triptan nonresponders.
- To review existing literature on triptan nonresponse.
- To outline challenges and propose a study design for investigating triptan nonresponders.
Main Methods:
- Literature review of clinical studies on triptan efficacy and nonresponse.
- Discussion of the complexities in defining and studying triptan nonresponders.
- Proposal for a pragmatic study design to assess the existence of a triptan nonresponder subpopulation.
Main Results:
- Currently, no definitive scientific data exist to confirm a distinct triptan nonresponder population.
- Evidence suggests that switching triptans can be effective for some non-responders.
- Systematic studies on patients unresponsive to all triptans and formulations are lacking.
Conclusions:
- The existence of a triptan nonresponder population remains unconfirmed by scientific data.
- A pragmatic study design is proposed to investigate this subpopulation.
- The complexity of nonresponse suggests multiple factors may be involved.
Related Concept Videos
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...